Amgen to Review Business with Analysts

Amgen (AMGN Quote) executives are expected to open up about their potential blockbuster bone-drug denosumab, or Dmab, and the company's pipeline at a business-review meeting on Friday.

As Amgen's anemia drug franchise has nearly halved on safety and reimbursement issues, Dmab, its late-stage osteoporosis drug, has become the focus for investors. Amgen presented promising late-stage data in the third quarter and said on its recent earnings conference call that it is close to filing an application for U.S. approval for the drug.

Street expectations for Dmab's market range from $500 million to more than $2 billion, according to Cowen and Co. ...